期刊文献+

卵巢癌组织中miR-377的表达及其与临床病理参数的关系 被引量:1

Expression level of miR-377 in ovarian cancer tissues,and its relationship with clinicopathological parameters
下载PDF
导出
摘要 目的:考察卵巢癌组织中miR-377的表达,分析miR-377表达与临床病理参数及预后的相关性。方法:收集卵巢癌组织及同期正常卵巢组织标本各50例,分别设为卵巢癌组及对照组,并收集病人临床病理参数资料。采用RT-qPCR技术检测2组样本的中miR-377的表达水平,分析miR-377与卵巢癌病人相关临床病理参数的关系,采用生存曲线图分析miR-377表达与预后的关系,并采用多因素COX回归分析卵巢癌预后的独立危险因素。结果:卵巢癌组miR-377表达低于对照组,差异有统计学意义(P<0.01)。卵巢癌组miR-377表达与肿瘤的TNM分期、临床分期、是否转移有关(P<0.05~P<0.01),与病人的年龄、卵巢癌类型等临床病理参数无关(P>0.05)。miR-377低表达者5年总生存率55.88%显著低于高表达者75.00%(P<0.01)。多因素COX回归分析显示,miR-377低表达与TNM分期是卵巢癌预后的独立危险因素(P<0.01)。结论:miR-377在卵巢癌病人组织中的表达显著降低,miR-377表达水平与卵巢癌病人的TNM分期、临床分期及病理分级有关,且miR-377低表达与TNM分期可视为卵巢癌预后的独立危险因素。 Objective:To investigate the expression level of miR-377 in ovarian cancer tissues,and analyze the correlation between miR-377 expression,and clinicopathological parameters and prognosis of patients.Methods:Fifty ovarian cancer tissue samples and 50 normal ovarian tissue samples were divided into the ovarian cancer group and control group,respectively.The clinical pathological parameters data were collected.The expression levels of miR-377 in two groups were detected using RT-qPCR,and the relationship between mir-377 expression and relevant clinical pathological parameters in ovarian cancer patients were analyzed.The relationship between mir-377 expression and prognosis was analyzed using survival curve,and the independent risk factors of ovarian cancer prognosis using multivariate COX regression method.Results:The expression level of miR-377 in ovarian cancer group was significantly lower than that in control group(P<0.01).The expression level of miR-377 in ovarian cancer group was correlated with the TNM stage,clinical stage and metastasis of tumor(P<0.05 to P<0.01),and not related to the age and ovarian cancer type of clinicopathological parameters(P>0.05).The 5-year survival rate of patient with low expression of miR-377(55.88%)was significantly lower than that in patients with high expression(75.00%)(P<0.01).The results of multivariate COX regression analysis showed that the low expression of miR-377 and TNM staging were the independent risk factors of ovarian cancer prognosis(P<0.01).Conclusions:The expression level of miR-377 in the ovarian cancer tissues decreases significantly.The expression levels of miR-377 is related to the TNM stage,clinical stage and pathological grade of ovarian cancer,and the low expression of miR-377 and TNM stage are the independent risk factors of the prognosis of patients with ovarian cancer.
作者 杨晓东 YANG Xiao-dong(Department of Gynecology,The First Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233004,China)
出处 《蚌埠医学院学报》 CAS 2021年第2期210-213,共4页 Journal of Bengbu Medical College
关键词 卵巢肿瘤 miR-377 临床病理参数 ovarian neoplasms miR-377 clinicopathological parameter
  • 相关文献

参考文献5

二级参考文献33

  • 1阿娜古丽.阿巴白克力,古丽娜.阿巴拜克力,徐克尔汗.塞地.64例上皮性卵巢癌的临床及预后分析[J].新疆医科大学学报,2006,29(3):245-247. 被引量:2
  • 2Sant M, Aareleid T, Berrino F, et al. EUROCARE-3 : Survival of canc- er patients diagnosed 1990-94-results and commentary [J]. Ann On- col,2003,14 (5) :61.
  • 3Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high risk, early stage epithelial ovarian cancer [J].Gynecol 0n- col,2010,116 (1) :57.
  • 4Cooper BC, Sood AK, Davis CS, et al. Preoperative CA 125 levels : an independent prognostic fact or for epithelial ovarian cancer [ J ]. Ob- stet Gynecol,2002,100 ( 1 ) :59.
  • 5Van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients[J].Gynecol Oncol,2000,79 (3) :444.
  • 6Rustin GJ, Marples M, Nelstrop AE, et al. Use.of CA125 to define pro- gression of ovarian cancer in patients with persistently elevated levels [J]. J Clin Oncol,2001,19 (20) :4054.
  • 7Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a ris- ing serum CA-125 within the normal range in patients with epithelial ovarian cancer : a preliminary investigation [ J ]. Gynecol Oncol, 2003, 89 (2) :233.
  • 8Higuchi M, Yamayoshi A, Kobori A, et al. Selective regulation of mu- tant K-ras mRAN expression by photo-cross-linking antisense oligonu- eleotide[J]. Nucleic Acids Symposium Series(Oxf) ,2007,51:443.
  • 9Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous o- varian carcinoma[ J ]. J Mol Med,2006,84 ( 8 ) i671.
  • 10Stadlmann S, Gueth U, Reiser U, et al. Epithelial growth factor recep- tor status in primary and recurrent ovarian cancer [J].Mod Pathel, 2006,19(4) :607.

共引文献190

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部